Medicare Enrolled
Dr. Manuel Castro-Borobio, M.D.
Infectious Disease · Roswell, GA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Castro-Borobio from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Castro-Borobio?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Castro-Borobio
Dr. Manuel Castro-Borobio is an infectious disease specialist in Roswell, GA, with 14 years of NPI registration. Based on federal Medicare data, Dr. Castro-Borobio performed 258,296 Medicare services across 1,081 unique beneficiaries.
Between the years covered by Open Payments, Dr. Castro-Borobio received a total of $7,484 from 44 pharmaceutical and/or device companies across 356 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in infectious disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Castro-Borobio is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 14 years in practice
▲ Top 2% volume in GA
$7,484 industry payments
Medicare Practice Summary
Medicare Utilization ↗258,296
Medicare services
Top 2% in GA for infectious disease
1,081
Unique beneficiaries
$3
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~18,450 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Daptomycin antibiotic injection | 240,151 | $0 | $0 |
| Privigen immune globulin injection, 500 mg An intravenous injection of Privigen, a non-lyophilized immune globulin product, administered in a 500 mg dose. |
8,540 | $37 | $72 |
| Denosumab injection (Prolia/Xgeva) | 1,620 | $18 | $35 |
| Ceftriaxone antibiotic injection This code represents the administration of ceftriaxone sodium, an antibiotic medication. The charge is calculated for every 250 mg of the drug administered. |
1,436 | $0 | $1 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
1,427 | $51 | $144 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
940 | $62 | $158 |
| Ertapenem sodium injection, 500 mg An injection of ertapenem sodium, an antibiotic medication, administered at a dose of 500 mg. |
910 | $11 | $26 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
905 | $98 | $231 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
363 | $12 | $31 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
339 | $16 | $44 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
321 | $23 | $63 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
316 | $8 | $13 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
208 | $92 | $220 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
169 | $1 | $1 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
164 | $100 | $292 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
163 | $11 | $35 |
| Wound tissue removal, 20 sq cm or less This procedure involves the removal of tissue from a wound area measuring 20 square centimeters or less. |
134 | $80 | $198 |
| Methylprednisolone injection, up to 40 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, administered in a dose of up to 40 mg. |
88 | $3 | $6 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
42 | $134 | $333 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
23 | $71 | $152 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
22 | $133 | $443 |
| Infusion tube insertion with imaging guidance A radiologist inserts an infusion tube into the body while using imaging guidance to ensure proper placement and reviews the procedure. |
15 | $313 | $673 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
0.9% high complexity
98.1% medium
1.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$7,484
Total received (2018-2024)
Avg $1,069/year across 7 years
Top 20% in GA for infectious disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
44
Companies
356
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$7,484 (100.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$466
2023
$121
2022
$146
2021
$3,520
2020
$1,371
2019
$1,096
2018
$763
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
ViiV Healthcare Company
$156
Gilead Sciences, Inc.
$94
Insmed, Inc.
$88
Melinta Therapeutics, LLC
$36
Merck Sharp & Dohme LLC
$29
PFIZER INC.
$28
TerSera Therapeutics LLC
$20
Paratek Pharmaceuticals, Inc.
$15
Top 3 companies account for 72.6% of 2024 payments
All-time payments by company (2018-2024) ›
CIPLA USA INC.
$1,264
Gilead Sciences, Inc.
$715
ViiV Healthcare Company
$714
Octapharma USA, Inc.
$604
Paratek Pharmaceuticals, Inc.
$520
Merck Sharp & Dohme Corporation
$446
Melinta Therapeutics, Inc.
$348
Insmed, Inc.
$287
AbbVie Inc.
$237
Janssen Biotech, Inc.
$228
Amgen Inc.
$221
AstraZeneca Pharmaceuticals LP
$182
Allergan Inc.
$173
Allergan, Inc.
$150
La Jolla Pharmaceutical Company
$145
Genentech USA, Inc.
$130
Takeda Pharmaceuticals U.S.A., Inc.
$114
MAYNE PHARMA INC.
$104
TETRAPHASE PHARMACEUTICALS, INC.
$87
Astellas Pharma US Inc
$74
PFIZER INC.
$66
Grifols USA, LLC
$63
CSL Behring
$55
Cumberland Pharmaceuticals, Inc.
$53
Melinta Therapeutics, LLC
$53
Nabriva Therapeutics, plc
$49
Smith+Nephew, Inc.
$44
Mylan Pharmaceuticals Inc.
$39
Merck Sharp & Dohme LLC
$29
Theratechnologies Inc.
$27
Mylan Institutional Inc.
$26
Shionogi Inc
$24
Horizon Therapeutics plc
$23
Kedrion Biopharma Inc.
$22
Kerecis Limited
$21
TerSera Therapeutics LLC
$20
Theravance Biopharma, Inc.
$19
Shire North American Group Inc
$19
TG THERAPEUTICS, INC.
$19
AbbVie, Inc.
$16
Novartis Pharmaceuticals Corporation
$14
GENZYME CORPORATION
$13
ABBVIE INC.
$12
Napo Pharmaceuticals Inc
$12
Top 3 companies account for 36.0% of all-time payments
Associated products mentioned in payments ›
APRETUDE · AVSOLA · AVYCAZ · Aimovig · Arikayce · BRIUMVI · Baxdela · CABENUVA · CRESEMBA · CUTAQUIG · CUVITRU · Cimduo · DALVANCE · DIFICID · DORYX · DOVATO · EVENITY · FASENRA · Fetroja · GAMMAKED · GATTEX · GRAFIX PL · HYQVIA · Hizentra · INFLECTRA · ISENTRESS · JULUCA · KRYSTEXXA · Kerecis Omega3 Wound · LEMTRADA · MAVYRET · MYCAMINE · Mavyret · Mytesi · NOXAFIL · NUZYRA · OCREVUS · Orbactiv · PANZYGA · PIFELTRO · PREVNAR - 13 · PREZCOBIX · PREZISTA · Prolastin-C Liquid · Prolia · Quzyttir · RUKOBIA · Rezzayo · SYMTUZA · Sivextro · Symfi Lo · Symtuza · TRIUMEQ · TROGARZO · VIBATIV · Vabomere · Vibativ · XERAVA · XOLAIR · Xembify · Xenleta · Xerava · ZEMDRI (PLAZOMICIN) · ZERBAXA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Infectious diseases within 10 mi
196
Per 100K population
18.3
County median income
$91,490
Nearest hospital
WELLSTAR NORTH FULTON MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Castro-Borobio is a mixed practice specialist, with above-average Medicare volume (top 2% in GA), with low-engagement industry engagement in the top 20% of GA peers.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Castro-Borobio experienced with daptomycin antibiotic injection?
Based on Medicare claims data, Dr. Castro-Borobio performed 240,151 daptomycin antibiotic injection services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Castro-Borobio receive payments from pharmaceutical companies?
Yes. Dr. Castro-Borobio received a total of $7,484 from 44 companies across 356 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Castro-Borobio's costs compare to other infectious diseases in Roswell?
Dr. Castro-Borobio's average Medicare payment per service is $3. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Castro-Borobio) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Infectious Diseases in Roswell
Browse infectious diseases in Roswell ranked by procedure volume and transparency data.
Highest volume
Top Infectious Diseases in GA
Infectious diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Infectious Diseases in GA
Which GA infectious diseases receive the most from drug and device companies.
By company
CIPLA USA INC. Payments to Doctors
See all physicians who received payments from CIPLA USA INC.
By company
Gilead Sciences, Inc. Payments to Doctors
See all physicians who received payments from Gilead Sciences, Inc.
By company
ViiV Healthcare Company Payments to Doctors
See all physicians who received payments from ViiV Healthcare Company.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology